Circulating tumor cells and drug history in primary breast cancer patients

Abstract

Aim: Different types of chronic medication may affect breast cancer prognosis. Circulating tumor cells (CTCs) play an important role in cancer metastasis formation. There is no evidence of how chronic medication affects CTCs and breast cancer prognosis. The aim of this study was to evaluate association between chronic medication and CTCs in patients with primary breast cancer.

Methods: This study involved 414 patients with stage I-III primary breast cancer. Chronic drug history was collected from patients’ medical records and included all drugs that were prescribed for patients over at least the last 6 months prior to CTCs evaluation. CTCs were detected using a quantitative real-time polymerase chain reaction (qRT-PCR)-based method at the time of breast surgery.

Results: There was no association between CTCs, including their different subpopulations and chronic medication. Chronic medication using angiotensin-converting-enzyme inhibitors (ACEi), metformin, and insulin were associated with inferior disease-free survival (HR = 0.49, 95%CI 0.26-0.94, P = 0.007 for ACEi; HR = 0.27, 95%CI 0.08-0.91, P < 0.001 for metformin; and HR = 0.12, 95%CI 0.01-2.91, P < 0.001 for insulin) and this was most pronounced in patients with epithelial to mesenchymal transition (CTC_EMT) phenotype. In multivariate analysis, chronic administration of metformin and/or insulin was an independent predictor of inferior outcome.

Conclusion: Our findings show that there was no association between chronically used medication and CTCs in primary breast cancer patients. However, administration of ACEi, metformin, and/or insulin could negatively affect prognosis of patients with CTC_EMT.

Keywords

Circulating tumor cells / chronic medication / epithelial-to-mesenchymal transition / early breast cancer

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Fidler IJ.Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxyuridine..J Natl Cancer Inst1970;45:773-82

[3] Aceto N,Miyamoto DT,Wittner BS.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis..Cell2014;158:1110-22 PMCID:PMC4149753

[4] Cristofanilli M,Ellis MJ,Matera J.Circulating tumor cells, disease progression, and survival in metastatic breast cancer..N Engl J Med2004;351:781-91

[5] Ignatiadis M,Ntoulia M,Apostolaki S.Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer..Clin Cancer Res2008;14:2593-600

[6] Lucci A,Lodhi AK,Anderson AE.Circulating tumour cells in non-metastatic breast cancer: a prospective study..Lancet Oncol2012;13:688-95

[7] Zhang L,Wu G,Yang K.Meta-analysis of the prognostic value of circulating tumor cells in breast cancer..Clin Cancer Res2012;18:5701-10

[8] Eliassen AH,Rosner B,Hankinson SE.Adult weight change and risk of postmenopausal breast cancer..JAMA2006;296:193-201

[9] Kawai M,Kuriyama S,Kakugawa Y.Adiposity, adult weight change and breast cancer risk in postmenopausal Japanese women: the Miyagi Cohort Study..Br J Cancer2010;103:1443-7 PMCID:PMC2990597

[10] Lahmann PH,Allen N,Khaw KT.Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC)..Int J Cancer2004;111:762-71

[11] Ulrich CM,Potter JD.Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics..Nat Rev Cancer2006;6:130-40

[12] Alimova IN,Fan Z,Dillon T.Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro..Cell Cycle2009;8:909-15

[13] Baneres Amella J,Anto Boque JM.The appropriateness of hospital admissions..Med Clin (Barc)1990;95:357-8

[14] Mu L,Zhang J,Li D.Type 2 diabetes, insulin treatment and prognosis of breast cancer..Diabetes Metab Res Rev2017;33:

[15] Mego M,De Giorgi U,Hsu L.Circulating tumor cells in newly diagnosed inflammatory breast cancer..Breast Cancer Res2015;17:2 PMCID:PMC4318180

[16] Brewer TM,Liu DD,Liu P.Statin use in primary inflammatory breast cancer: a cohort study..Br J Cancer2013;109:318-24 PMCID:PMC3721387

[17] Mego M,Minarik G,Silvia J.Circulating tumor cells with epithelial-to-mesenchymal transition phenotypes associated with inferior outcomes in primary breast cancer..Anticancer Res2019;39:1829-37

[18] Cierna Z,Janega P,Minarik G.Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer..BMC Cancer2014;14:472 PMCID:PMC4079912

[19] Mego M,Minarik G,Sedlackova T.Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients..Breast J2015;21:155-60

[20] Mego M,Minarik G,Gronesova P.CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer..BMC Cancer2016;16:127 PMCID:PMC4759765

[21] Peairs KS,Snyder CF,Stein KB.Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis..J Clin Oncol2011;29:40-6 PMCID:PMC3055858

[22] Wairagu PM,Kim MK,Kim HW.Insulin priming effect on estradiol-induced breast cancer metabolism and growth..Cancer Biol Ther2015;16:484-92 PMCID:PMC4622942

[23] Gunter MJ,Yu H,Rohan TE.Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women..J Natl Cancer Inst2009;101:48-60 PMCID:PMC2639294

[24] Gonzalez-Angulo AM.Metformin: a therapeutic opportunity in breast cancer..Clin Cancer Res2010;16:1695-700 PMCID:PMC2840206

[25] Jiralerspong S,Giordano SH,Liedtke C.Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer..J Clin Oncol2009;27:3297-302 PMCID:PMC2736070

[26] Chae YK,Lei X,Giordano SH.Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes..J Cancer2013;4:549-56 PMCID:PMC3753529

[27] Sorensen GV,Cole SW,Sorensen HT.Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study..J Clin Oncol2013;31:2265-72 PMCID:PMC3677839

[28] Ganz PA,Weltzien EK,Cole SW.Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort..Breast Cancer Res Treat2011;129:549-56 PMCID:PMC3145014

[29] Holmes MD,Feskanich D.Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use..Breast Cancer Res Treat2013;139:507-13 PMCID:PMC3683855

[30] Cardwell CR,Hicks BM,Cantwell MM.Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts..BMC Med2014;12:28 PMCID:PMC3926686